Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells

Journal of Cellular Biochemistry

Volumn 112, Issue 10, 2011, Pages 3044-3053

  Li, Chien Te ^a,b   Hsiao, Yi Min ^c   Wu, Tzu Chin ^a,d   Lin, Yu Wen ^a   Yeh, Kun Tu ^a,b   Ko, Jiunn Liang ^a,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

epigenetic regulation; hTERT; lung cancer; telomerase activity; vorinostat

Indexed keywords

DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; GENOMIC DNA; HISTONE H3; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR SP1; VORINOSTAT;

ARTICLE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INACTIVATION; ENZYME INHIBITION; EPIGENETIC REGULATION; EPIGENETICS; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE;

EID: 80053207760     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23229     Document Type: Article

References (50)

1. Abdul-Ghani R, Ohana P, Matouk I, Ayesh S, Ayesh B, Laster M, Bibi O, Giladi H, Molnar-Kimber K, Sughayer MA, de Groot N, Hochberg A,. 2000. Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells. Mol Ther 2: 539-544.
2. Arnold NB, Arkus N, Gunn J, Korc M,. 2007. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin Cancer Res 13: 18-26. (Pubitemid 46121848)
3. Bechter OE, Eisterer W, Dlaska M, Kuhr T, Thaler J,. 2002. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol 30: 26-33. (Pubitemid 34059214)
4. Bouchain G, Delorme D,. 2003. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: Synthesis and antiproliferative evaluation. Curr Med Chem 10: 2359-2372. (Pubitemid 37236393)
5. Choi YH,. 2005. Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells. Int J Oncol 27: 473-479.
6. Choi JH, Min NY, Park J, Kim JH, Park SH, Ko YJ, Kang Y, Moon YJ, Rhee S, Ham SW, Park AJ, Lee KH,. 2010. TSA-induced DNMT1 down-regulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116. Biochem Biophys Res Commun 391: 449-454.
7. Curtin M, Glaser K,. 2003. Histone deacetylase inhibitors: The Abbott experience. Curr Med Chem 10: 2373-2392. (Pubitemid 37236394)
8. Damiani LA, Yingling CM, Leng S, Romo PE, Nakamura J, Belinsky SA,. 2008. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res 68: 9005-9014.
9. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR,. 2007. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39. (Pubitemid 46053039)
10. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW,. 2000. MethyLight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32.
11. Fedier A, Dedes KJ, Imesch P, Von Bueren AO, Fink D,. 2007. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Int J Oncol 31: 633-641.
12. Ge Z, Li W, Wang N, Liu C, Zhu Q, Bjorkholm M, Gruber A, Xu D,. 2010. Chromatin remodeling: Recruitment of histone demethylase RBP2 by Mad1 for transcriptional repression of a Myc target gene, telomerase reverse transcriptase. FASEB J 24: 579-586.
13. Guilleret I, Benhattar J,. 2003. Demethylation of the human telomerase catalytic subunit (hTERT) gene promoter reduced hTERT expression and telomerase activity and shortened telomeres. Exp Cell Res 289: 326-334. (Pubitemid 37117418)
14. Guilleret I, Yan P, Grange F, Braunschweig R, Bosman FT, Benhattar J,. 2002. Hypermethylation of the human telomerase catalytic subunit (hTERT) gene correlates with telomerase activity. Int J Cancer 101: 335-341. (Pubitemid 34983188)
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB,. 1996. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826. (Pubitemid 26296693)
16. Hou M, Wang X, Popov N, Zhang A, Zhao X, Zhou R, Zetterberg A, Bjorkholm M, Henriksson M, Gruber A, Xu D,. 2002. The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells. Exp Cell Res 274: 25-34.
17. Hsin IL, Sheu GT, Chen HH, Chiu LY, Wang HD, Chan HW, Hsu CP, Ko JL,. 2010. N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549cells. Mutat Res 688: 72-77.
18. Huang C, Ida H, Ito K, Zhang H, Ito Y,. 2007. Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem Pharmacol 73: 990-1000.
19. Huang PH, Chen CH, Chou CC, Sargeant AM, Kulp SK, Teng CM, Byrd JC, Chen CS,. 2010. Histone deacetylase inhibitors stimulate histone h3 lysine 4 methylation in part via transcriptional repression of histone h3 lysine 4 demethylases. Mol Pharmacol 79: 197-206.
20. James SR, Link PA, Karpf AR,. 2006. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 25: 6975-6985. (Pubitemid 44684838)
21. Johnstone RW, Ruefli AA, Lowe SW,. 2002. Apoptosis: A link between cancer genetics and chemotherapy. Cell 108: 153-164. (Pubitemid 34161136)
22. Kageyama Y, Kamata S, Yonese J, Oshima H,. 1997. Telomere length and telomerase activity in bladder and prostate cancer cell lines. Int J Urol 4: 407-410. (Pubitemid 127497501)
23. Kitagawa Y, Kyo S, Takakura M, Kanaya T, Koshida K, Namiki M, Inoue M,. 2000. Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT. Clin Cancer Res 6: 2868-2875. (Pubitemid 30482129)
24. Komata T, Kanzawa T, Kondo Y, Kondo S,. 2002. Telomerase as a therapeutic target for malignant gliomas. Oncogene 21: 656-663. (Pubitemid 34146268)
25. Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP,. 2006. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 15: 187-191.
26. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M,. 2000. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28: 669-677. (Pubitemid 30068249)
27. Kyo S, Takakura M, Fujiwara T, Inoue M,. 2008. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 99: 1528-1538.
28. Landberg G, Nielsen NH, Nilsson P, Emdin SO, Cajander J, Roos G,. 1997. Telomerase activity is associated with cell cycle deregulation in human breast cancer. Cancer Res 57: 549-554. (Pubitemid 27081678)
29. Lee EJ, Lee BB, Kim SJ, Park YD, Park J, Kim DH,. 2008. Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells. Int J Oncol 33: 767-776.
30. Li Y, Liu L, Andrews LG, Tollefsbol TO,. 2009. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer 125: 286-296.
31. Lin SC, Li WC, Shih JW, Hong KF, Pan YR, Lin JJ,. 2006. The tea polyphenols EGCG and EGC repress mRNA expression of human telomerase reverse transcriptase (hTERT) in carcinoma cells. Cancer Lett 236: 80-88.
32. Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G,. 2008. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California Cancer Consortium study. Clin Cancer Res 14: 7138-7142.
33. Marchetti A, Bertacca G, Buttitta F, Chella A, Quattrocolo G, Angeletti CA, Bevilacqua G,. 1999. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res 5: 2077-2081. (Pubitemid 29399261)
34. Marks PA, Xu WS,. 2009. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608.
35. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK,. 2001. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1: 194-202. (Pubitemid 33741894)
36. Meeran SM, Patel SN, Tollefsbol TO,. 2010. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One 5: e11457.
37. Meeran SM, Patel SN, Tollefsbol TO,. 2011 Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One 5: e11457.
38. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM,. 2001. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61: 8492-8497. (Pubitemid 33131130)
39. Ou JN, Torrisani J, Unterberger A, Provencal N, Shikimi K, Karimi M, Ekstrom TJ, Szyf M,. 2007. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 73: 1297-1307. (Pubitemid 46452588)
40. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA,. 2010. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 126: 743-755.
41. Renaud S, Loukinov D, Abdullaev Z, Guilleret I, Bosman FT, Lobanenkov V, Benhattar J,. 2007. Dual role of DNA methylation inside and outside of CTCF-binding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res 35: 1245-1256. (Pubitemid 46522976)
42. Ting AH, McGarvey KM, Baylin SB,. 2006. The cancer epigenome-Components and functional correlates. Genes Dev 20: 3215-3231.
43. Wang S, Hu C, Zhu J,. 2010. Distinct and temporal roles of nucleosomal remodeling and histone deacetylation in the repression of the hTERT gene. Mol Biol Cell 21: 821-832.
44. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ,. 2010. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol 65: 979-988.
45. Witta SE, Dziadziuszko R, Yoshida K, Hedman K, Varella-Garcia M, Bunn PA, Jr, Hirsch FR,. 2009. ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC). Ann Oncol 20: 689-695.
46. Won J, Yim J, Kim TK,. 2002. Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells. J Biol Chem 277: 38230-38238. (Pubitemid 35154677)
47. Wu TC, Lin P, Hsu CP, Huang YJ, Chen CY, Chung WC, Lee H, Ko JL,. 2003. Loss of telomerase activity may be a potential favorable prognostic marker in lung carcinomas. Lung Cancer 41: 163-169. (Pubitemid 36842779)
48. Yan P, Saraga EP, Bouzourene H, Bosman FT, Benhattar J,. 1999. Telomerase activation in colorectal carcinogenesis. J Pathol 189: 207-212. (Pubitemid 29448914)
49. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA,. 2001. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61: 1327-1333. (Pubitemid 34292551)
50. Zinn RL, Pruitt K, Eguchi S, Baylin SB, Herman JG,. 2007. hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res 67: 194-201. (Pubitemid 46142775)